Figures & data
Figure 1 Pathological roles of interleukin-6 in rheumatoid arthritis. Constitutive overproduction of interleukin-6, a pleiotropic cytokine that regulates the immune system, inflammation, hematopoiesis, and bone metabolism, is thought to play pathologic roles in rheumatoid arthritis.
![Figure 1 Pathological roles of interleukin-6 in rheumatoid arthritis. Constitutive overproduction of interleukin-6, a pleiotropic cytokine that regulates the immune system, inflammation, hematopoiesis, and bone metabolism, is thought to play pathologic roles in rheumatoid arthritis.](/cms/asset/6af02cac-d332-41b8-ba49-108b0a9fedd7/dbtt_a_1828_f0001_b.jpg)
Figure 2 Signal transduction of interleukin (IL)-6 /IL-6 receptor (R) complex via gp130 and the mechanism of signal transduction blockage by tocilizumab. IL-6 signal is mediated via IL-6R on the cell surface or soluble form of IL-6R, followed by dimerization of the signal transducer gp-130, which is bound to the IL-6/IL-6R complex. Tocilizumab inhibits the binding of IL-6 to IL-6R or sIL-6R.
![Figure 2 Signal transduction of interleukin (IL)-6 /IL-6 receptor (R) complex via gp130 and the mechanism of signal transduction blockage by tocilizumab. IL-6 signal is mediated via IL-6R on the cell surface or soluble form of IL-6R, followed by dimerization of the signal transducer gp-130, which is bound to the IL-6/IL-6R complex. Tocilizumab inhibits the binding of IL-6 to IL-6R or sIL-6R.](/cms/asset/f2e26a1b-7f31-4178-a084-a94b53809173/dbtt_a_1828_f0002_c.jpg)
Figure 3 The incidence of a 20% improvement in disease activity according to the American College of Rheumatology (ACR) criteria at week 12. Tocilizumab treatment significantly improved all measures of disease activity in the ACR core set, and a dose-response relationship was observed between the 4-mg and 8-mg groups. Adapted with permission from CitationNishimoto N, Yoshizaki K, Miyasaka N, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 50:1761–9. Copyright © 2004. Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
![Figure 3 The incidence of a 20% improvement in disease activity according to the American College of Rheumatology (ACR) criteria at week 12. Tocilizumab treatment significantly improved all measures of disease activity in the ACR core set, and a dose-response relationship was observed between the 4-mg and 8-mg groups. Adapted with permission from CitationNishimoto N, Yoshizaki K, Miyasaka N, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 50:1761–9. Copyright © 2004. Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.](/cms/asset/a9ad1d8e-8c07-41d0-b1bb-db7861e3bc88/dbtt_a_1828_f0003_b.jpg)
Table 1 DAS28 remission (<2.6)% improvement scores among tocilizumab’s clinical studies. Tocilizumab treatment significantly improved the measures of DAS28 scores compared to the control group. Adapted from CitationNishimoto et al (2006b)